Adenoma differential diagnosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(4 intermediate revisions by 4 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Adenoma}}
[[Image:Home_logo1.png|right|250px|link=https://www.wikidoc.org/index.php/Adenoma]]
Please help WikiDoc by adding content hereIt's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing.
 
Adrenal adenoma must be differentiated from other adrenal tumors such as , adrenal [[metastasis]], [[Pheochromocytoma|adrenal medullary tumors]], and [[Cushing's syndrome]].
{| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px" align="center"
 
|+
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Differential Diagnosis}}
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|Clinical picture}}
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|Imagings}}
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|Laboratory tests}}
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''Adrenocortica'''l carcinoma
| style="padding: 5px 5px; background: #F5F5F5;" |
* Mass effect symptoms
* Symptoms related to  excess [[glucocorticoid]]
* Symptoms related to  excess [[mineralocorticoid]]
* Symptoms related to  excess [[androgen]] or [[estrogen]] secretion
|
* Irregular shape
* Non-[[homogeneous]] density because of central areas of low attenuation due to [[tumor]] [[necrosis]]
* [[Tumor]] [[calcification]]
* Diameter usually >4 cm
* Unilateral location
* High unenhanced [[Computed tomography|CT]] attenuation values (>20 HU)
* Non-[[homogeneous]] enhancement on [[Computed tomography|CT]] with [[intravenous]] [[Contrast medium|contrast]]
* Delay in [[contrast medium]] washout (10 minutes after administration of [[contrast]], an absolute [[contrast medium]] washout of less than 50 percent)
* Hypointensity compared with [[liver]] on T1 weighted [[Magnetic resonance imaging|MRI]] and high to intermediate signal intensity on T2 weighted [[Magnetic resonance imaging|MRI]]
* High standardized uptake value (SUV) on [[FDG-PET|FDG]]-[[PET scan|PET-CT]] study
* Evidence of local [[invasion]] or [[Metastasis|metastases]]
|
* [[Androgen|Adrenal androgens]] ([[DHEAS|DHEAS)]]
* [[Androstenedione]]
* Bioavailable [[testosterone]] should be measured in every patient.
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]]
* Serum [[estradiol]] in men and postmenopausal women
* [[Cortisol level]]
* Fasting serum [[cortisol]] at 8 AM following a 1 mg dose of [[dexamethasone]] at bedtime
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Adrenal adenoma]]
| style="padding: 5px 5px; background: #F5F5F5;" |
* Symptoms related to excess [[glucocorticoid]]
* Symptoms related to excess [[mineralocorticoid]]
|
* Round, [[homogeneous]] with sharp margination
* Unilateral with diameter less than 4 cm
* Low unenhanced [[Computed tomography|CT]] attenuation values (<10 HU)
* Rapid [[contrast medium]] washout after administration of contrast
* An absolute [[contrast medium]] washout of more than 50 percent
* [[Chemical shift]]: evidence of [[lipid]] on [[Magnetic resonance imaging|MRI]]
* Isointensity with [[liver]] on both T1 and T2 weighted [[Magnetic resonance imaging|MRI]] sequences
|
* [[Cortisol level]]
* Fasting [[serum]] [[cortisol]] at 8 AM following a 1 mg dose of [[dexamethasone]] at bedtime
* [[Renin]] ([[Plasma renin activity|PRA]]) or plasma renin concentration (PRC): very low in patients with [[primary aldosteronism]], usually less than 1 ng/mL per hour for [[Plasma renin activity|PRA]] and usually undetectable for PRC<ref name="pmid26372319">{{cite journal| author=Manolopoulou J, Fischer E, Dietz A, Diederich S, Holmes D, Junnila R et al.| title=Clinical validation for the aldosterone-to-renin ratio and aldosterone suppression testing using simultaneous fully automated chemiluminescence immunoassays. | journal=J Hypertens | year= 2015 | volume= 33 | issue= 12 | pages= 2500-11 | pmid=26372319 | doi=10.1097/HJH.0000000000000727 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26372319 }}</ref>
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Cushing's syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" |
* Rapid [[Obesity|weight gain]], particularly of the [[trunk]] and [[face]] with [[limbs]] sparing ([[central obesity]])
* Proximal [[muscle weakness]]
* A [[round face]] often referred to as a "[[moon face]]"
* Excess [[sweating]]
* [[Headache]]
|
* Imaging may show [[mass]] if presents
|
* 24-hour [[urine]] [[cortisol]]
* Midnight salivary [[cortisol]]
* Low-dose [[dexamethasone]] suppression test; high [[cortisol]] level after the [[dexamethasone]] test is suggestive of [[hypercortisolism]].
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Pheochromocytoma]]
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Palpitations]] especially in [[Epinephrine|epinephrine-]]<nowiki/>producing [[Tumor|tumors]].
* [[Anxiety]] often resembling that of a [[panic attack]]
* [[Sweating]]
* [[Headaches]] occur in 90 % of patients.
* Paroxysmal attacks of [[hypertension]] but some patients have normal [[blood pressure]].
* It may be [[asymptomatic]] and discovered incidentally after [[Screening (medicine)|screening]] for [[MEN, type 2|MEN]] patients.
|
* Increased [[attenuation]] on non-enhanced [[Computed tomography|CT]] (>20 HU)
* Increased [[mass]] [[vascularity]]
* Delay in [[contrast medium]] washout (10 minutes after administration of [[contrast]], an absolute [[contrast medium]] washout of less than 50 percent)
* High signal intensity on T2 weighted [[Magnetic resonance imaging|MRI]]
* [[Cystic]] and [[hemorrhagic]] changes
* Variable size and may be [[bilateral]]
|
* [[Plasma]] fractionated [[Metanephrine|metanephrines]] 
* 24-hour [[urinary]] fractionated [[Metanephrine|metanephrines]]
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Adrenal metastasis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Symptoms]] and [[signs]] of primary [[malignancy]] especially [[lung cancer]]
* General constitutional symptoms:
**[[Fever]]
**[[Fatigue]]
**[[Weight loss]]
|
* Irregular shape and non-[[homogeneous]] nature
* Tendency to be [[bilateral]]
* High un-enhanced [[Computed tomography|CT]] [[attenuation]] values (>20 HU) and enhancement with [[Contrast medium|intravenous contrast]] on [[Computed tomography|CT]]
* Delay in [[contrast medium]] washout (10 minutes after administration of contrast, an absolute [[contrast medium]] washout of less than 50 percent)
* Isointensity or slightly less intense than the [[liver]] on T1 weighted [[Magnetic resonance imaging|MRI]] and high to intermediate signal intensity on T2 weighted [[Magnetic resonance imaging|MRI]] (representing an increased water content)
* Elevated standardized uptake value on [[FDG-PET|FDG]]-[[PET scan]]
|
|}
 
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
{{WH}}
{{WS}}
[[Category:Needs content]]
[[Category:Needs content]]
[[Category:Disease]]
[[Category:Pathology]]
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]

Latest revision as of 19:55, 6 March 2019

Adrenal adenoma must be differentiated from other adrenal tumors such as , adrenal metastasis, adrenal medullary tumors, and Cushing's syndrome.

Differential Diagnosis Clinical picture Imagings Laboratory tests
Adrenocortical carcinoma
Adrenal adenoma
Cushing's syndrome
  • Imaging may show mass if presents
Pheochromocytoma
Adrenal metastasis

References

  1. Manolopoulou J, Fischer E, Dietz A, Diederich S, Holmes D, Junnila R; et al. (2015). "Clinical validation for the aldosterone-to-renin ratio and aldosterone suppression testing using simultaneous fully automated chemiluminescence immunoassays". J Hypertens. 33 (12): 2500–11. doi:10.1097/HJH.0000000000000727. PMID 26372319.

Template:WH Template:WS